High lifetime, but low current, prevalence of new psychotropic substances (NPS) use in German drug detoxification treatment young inpatients.

Autor: Scherbaum N; LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany. Electronic address: norbert.scherbaum@uni-due.de., Seiffert F; LWL-Klinik Marsberg, Department of Psychiatry and Psychotherapy, Marsberg, Germany., Schifano F; University of Hertfordshire, 'Psychopharmacology, Substance Misuse and Novel Psychoactive Substances' Research Unit, Hatfield, Hertfordshire, United Kingdom., Specka M; LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany., Bonnet U; LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany; Evangelisches Krankenhaus Castrop-Rauxel, Klinik für Psychiatrie, Psychotherapie und Psychosomatische Medizin, Castrop-Rauxel, Germany., Bender S; LWL-Klinik Marsberg, Department of Psychiatry and Psychotherapy, Marsberg, Germany.
Jazyk: angličtina
Zdroj: Progress in neuro-psychopharmacology & biological psychiatry [Prog Neuropsychopharmacol Biol Psychiatry] 2021 Dec 20; Vol. 111, pp. 110144. Date of Electronic Publication: 2020 Oct 19.
DOI: 10.1016/j.pnpbp.2020.110144
Abstrakt: Background: Over the last 15 years, a large number of new psychoactive substances (NPS) has been identified, with their use being associated with a range of acute medical and psychopathological complications. Conversely, NPS addictive liability levels have not been systematically assessed in clinical populations.
Aims of the Study: Investigating the lifetime and current prevalence of NPS use in a sample of substance use disorder (SUD) patients admitted to an inpatient detoxification treatment centre.
Methods: Assessment of previous/current NPS intake carried out with the means of standardised questionnaire based on the European version of Addiction Severity Index.
Results: Some 206 patients (males 77.1%; average age: 30.7 years-old; most typical diagnosis: opioid/polydrug dependence) participated to the survey. Roughly half (e.g. 111/206; 53.9%) of them reported a lifetime use of NPS, most typically synthetic cannabinoids. Conversely, the current prevalence of NPS use was 2.9%; no NPS dependence condition was diagnosed. Among NPS users, 56.3% reported severe side-effects such as heavy anxiety or psychotic experience, and 64% reported an aversion of ever using the respective NPS again, whilst 84.3% of those reporting a single NPS intake reported an aversion.
Discussion: The sharp contrast between lifetime prevalence of NPS use and prevalence of current use might be explained by the high frequency of severe side effects reported by NPS users.
(Copyright © 2020. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: